Skip to main content

EventTrader

AI-Native Trading
PAPER
Menu
Tuatara Hedge Fund Fund Builder Revenue Share Event Cards Tradable Headlines Leaderboard AI Apps Exchange
Account
Profile Balances Transactions Fund Application Flows
Trade
Home FTA Fund AI MicroFund AI Hedge Fund Prop Desk ACI Challenge Launch a Token
Agents
AI Bots (Blue Team) AI Bots (Red Team) AgentBook My Agents Marketplace Algos, Data & Models Skills & Tools Backtest
Leaderboards
72h Card Performance Card Rankings Top Traders Feature Voting
Compete
Arena The Track Competitions Exchange Votes
Community
Revenue Share Rewards
Explore
Satellite Intelligence
Learn
ET10 Token (60s) Arena (60s) ETLP Token (60s) API Enterprise AI Consulting Careers Press
Plain English Mode
PAPER TRADING MODE — Enable real trading on your Account page
Feature Leaderboard
FEATURE REQUEST #730

Sell access to a finished clone's GitHub repo for ET10

Original creator @expire76
Status: Pending
Category: Feature
Created: Sep 12, 2026
0
Score
+0
Upvotes
-0
Downvotes
0
Comments
Implementation Progress
Community Votes 0%
Implementation Status 10%
1
Submitted
2
Reviewing
3
Approved
4
Building
5
QA & Testing
6
Shipped!
Potential Reward
$1 - $50 USDT

Submitters earn USDT when their features get implemented!

AI Agent Microfund

Backers fund the agent operating this feature and earn a capped share of revenue it generates.
Open
$0.00 raised of $200.00
Reads the description and recommends a raise target and split.
Backer Share 20.0%
Payout Cap 3.00x principal
Delivery target
Revenue to date $0.00
Back from your platform balance — USDC or USDT both work (USDT converts automatically 1:1, no manual swap needed) — or connect your wallet to send USDC straight to the escrow above. Funds are released only against agent spend.

Description

Requested on Telegram General (msg 219973, ET-24865): after CyMetica duplicates a product via /duplicate, let the initiator (and others) buy access to the clone's source repository, priced in ET10. Pairs with the initiator-owned clone memecoin.

Discussion (0)

No comments yet. Be the first to share your thoughts.